PortfoliosLab logoPortfoliosLab logo
NRIX vs. XBI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

NRIX vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NRIX achieves a -0.58% return, which is significantly lower than XBI's 20.70% return.


NRIX

1D
1.13%
1M
7.77%
YTD
-0.58%
6M
-2.23%
1Y
57.43%
3Y*
23.51%
5Y*
-8.61%
10Y*

XBI

1D
0.80%
1M
11.78%
YTD
20.70%
6M
17.84%
1Y
79.53%
3Y*
20.24%
5Y*
1.51%
10Y*
11.14%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NRIX vs. XBI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
NRIX
Nurix Therapeutics, Inc.
-0.58%0.69%82.56%-6.01%-62.07%-11.95%82.06%
XBI
SPDR S&P Biotech ETF
20.70%35.89%1.01%7.60%-25.87%-20.45%22.74%

Correlation

The correlation between NRIX and XBI is 0.61, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.61

Correlation (3Y)
Calculated over the trailing 3-year period

0.63

Correlation (5Y)
Calculated over the trailing 5-year period

0.66

Correlation (All Time)
Calculated using the full available price history since Jul 24, 2020

0.61

The correlation between NRIX and XBI has been stable across timeframes, ranging from 0.61 to 0.66 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Nurix Therapeutics, Inc.

SPDR S&P Biotech ETF

Return for Risk

NRIX vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NRIX
NRIX Risk / Return Rank: 6969
Overall Rank
NRIX Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
NRIX Sortino Ratio Rank: 7272
Sortino Ratio Rank
NRIX Omega Ratio Rank: 6767
Omega Ratio Rank
NRIX Calmar Ratio Rank: 7070
Calmar Ratio Rank
NRIX Martin Ratio Rank: 6666
Martin Ratio Rank

XBI
XBI Risk / Return Rank: 9090
Overall Rank
XBI Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
XBI Sortino Ratio Rank: 8989
Sortino Ratio Rank
XBI Omega Ratio Rank: 8282
Omega Ratio Rank
XBI Calmar Ratio Rank: 9696
Calmar Ratio Rank
XBI Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NRIX vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nurix Therapeutics, Inc. (NRIX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


NRIXXBIDifference
Sharpe ratioReturn per unit of total volatility

-2.08

Sortino ratioReturn per unit of downside risk

-2.12

Omega ratioGain probability vs. loss probability

1.20

1.47

-0.27

Calmar ratioReturn relative to maximum drawdown

1.54

8.22

-6.68

Martin ratioReturn relative to average drawdown

2.70

24.30

-21.59

NRIX vs. XBI - Sharpe Ratio Comparison

The current NRIX Sharpe Ratio is 0.94, which is lower than the XBI Sharpe Ratio of 3.02. The chart below compares the historical Sharpe Ratios of NRIX and XBI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

NRIX vs. XBI - Drawdown Comparison

The maximum NRIX drawdown since its inception was -91.53%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for NRIX and XBI.


Loading charts...

Drawdown Indicators


NRIXXBIDifference

Max Drawdown

Largest peak-to-trough decline

-91.53%

-63.89%

-27.64%

Max Drawdown (1Y)

Largest decline over 1 year

-37.48%

-9.72%

-27.76%

Max Drawdown (3Y)

Largest decline over 3 years

-70.72%

-32.99%

-37.73%

Max Drawdown (5Y)

Largest decline over 5 years

-88.42%

-54.71%

-33.71%

Max Drawdown (10Y)

Largest decline over 10 years

-63.89%

Current Drawdown

Current decline from peak

-62.41%

-14.94%

-47.47%

Average Drawdown

Average peak-to-trough decline

-61.58%

-20.93%

-40.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

21.31%

3.28%

+18.03%

Volatility

NRIX vs. XBI - Volatility Comparison

Nurix Therapeutics, Inc. (NRIX) has a higher volatility of 17.56% compared to SPDR S&P Biotech ETF (XBI) at 9.96%. This indicates that NRIX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NRIXXBIDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.56%

9.96%

+7.60%

Volatility (6M)

Calculated over the trailing 6-month period

35.51%

21.31%

+14.20%

Volatility (1Y)

Calculated over the trailing 1-year period

61.70%

26.47%

+35.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

73.24%

32.30%

+40.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.86%

32.01%

+47.85%

Dividends

NRIX vs. XBI - Dividend Comparison

NRIX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.39%.


PositionTTM20252024202320222021202020192018201720162015
NRIX
Nurix Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF
0.39%0.37%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%

Frequently Asked Questions


NRIX and XBI have a correlation of 0.61, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NRIX has higher volatility (17.56%) compared to XBI (9.96%). In terms of maximum drawdown, NRIX dropped -91.53% vs XBI's -63.89%.

XBI currently has the higher Sharpe Ratio (3.02 vs 0.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NRIX and XBI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer